Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.

Schochter F, Friedl TWP, Schäffler H, Meier-Stiegen F, Pfister KN, Riethdorf S, Wiesmüller L, Neubauer H, Müller L, Wimberger P, Fasching PA, Lorenz R, Hempel T, Heublein S, Hartkopf A, Pantel K, Rack B, Müller V, Fehm T, Janni W, Cieslik JP

Open source

DOI: 10.1007/s10549-026-08069-2
Published: 2026 Sep 16
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08069-2,
  title = {Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.},
  author = {Schochter F and Friedl TWP and Schäffler H and Meier-Stiegen F and Pfister KN and Riethdorf S and Wiesmüller L and Neubauer H and Müller L and Wimberger P and Fasching PA and Lorenz R and Hempel T and Heublein S and Hartkopf A and Pantel K and Rack B and Müller V and Fehm T and Janni W and Cieslik JP},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-08069-2},
  url = {https://doi.org/10.1007/s10549-026-08069-2}
}

RIS

TY  - JOUR
TI  - Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.
AU  - Schochter F
AU  - Friedl TWP
AU  - Schäffler H
AU  - Meier-Stiegen F
AU  - Pfister KN
AU  - Riethdorf S
AU  - Wiesmüller L
AU  - Neubauer H
AU  - Müller L
AU  - Wimberger P
AU  - Fasching PA
AU  - Lorenz R
AU  - Hempel T
AU  - Heublein S
AU  - Hartkopf A
AU  - Pantel K
AU  - Rack B
AU  - Müller V
AU  - Fehm T
AU  - Janni W
AU  - Cieslik JP
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-08069-2
UR  - https://doi.org/10.1007/s10549-026-08069-2
ER  -

APA

F, S., TWP, F., H, S., F, M., KN, P., S, R., L, W., H, N., L, M., P, W., PA, F., R, L., T, H., S, H., A, H., K, P., B, R., V, M., T, F., W, J., & JP, C. (2026). Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-08069-2

Source records

pubmed · retrieved 2026-11-10T08:58:52.614Z